first large study of glp 1 receptor agonists during pregnancy GLP-1 agonist exposure linked to complications PDF) Use of GLP1 receptor

Eur J Med Chem

doi: 10.1016/j.cmet.2019.07.013 [DOI] [PMC free article] [PubMed] [Google Scholar] 43.Harikumar KG, Wootten D, Pinon DI, et al

Economic evaluation of weight loss and transplantation strategies for kidney transplant candidates with obesity

95% confidence interval [CI], 3.69 to 2.30) [32]

Methods Study design Representatives of the companies Bristol-Myers Squibb, Novo Nordisk, Sanofi, Merck, Novartis, Boehringer Ingelheim and Takeda were contacted with the request to provide the event numbers of acute pancreatitis with the respective drug and non-incretin comparators as well as the corresponding number of patient-years of exposure (PYOs) for the approved GLP-1 receptor agonists exenatide twice daily, exenatide weekly, liraglutide and lixisenatide, as well as the DPP-4 inhibitors sitagliptin, saxagliptin, vildagliptin, alogliptin and linagliptin

Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial